Trials / Completed
CompletedNCT00889889
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,270 (actual)
- Sponsor
- Abbott Biologicals · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Immunogenicity and safety of a cell-derived influenza vaccine in adults aged \>= 18 and \<= 64 years, plus revaccination
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cell-Derived Trivalent Subunit Influenza Vaccine | surface antigen, inactivated, prepared in cell cultures |
| BIOLOGICAL | Placebo | Placebo |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-04-29
- Last updated
- 2013-10-25
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00889889. Inclusion in this directory is not an endorsement.